Arrowstreet Capital Limited Partnership Trims Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Arrowstreet Capital Limited Partnership lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 25.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,541,058 shares of the company's stock after selling 527,921 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.50% of Amneal Pharmaceuticals worth $12,205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in shares of Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock valued at $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock valued at $31,511,000 after acquiring an additional 378,136 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at about $2,946,000. Prudential Financial Inc. boosted its position in shares of Amneal Pharmaceuticals by 29.6% during the 4th quarter. Prudential Financial Inc. now owns 1,183,781 shares of the company's stock valued at $9,376,000 after acquiring an additional 270,200 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Amneal Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock valued at $117,548,000 after acquiring an additional 218,025 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock traded down $0.47 during trading hours on Thursday, reaching $6.96. The company had a trading volume of 434,170 shares, compared to its average volume of 1,394,087. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.18 and a 12-month high of $9.48. The company has a 50-day moving average price of $8.22 and a 200 day moving average price of $8.30. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -10.24 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $730.52 million during the quarter, compared to analysts' expectations of $708.21 million. During the same period in the previous year, the firm earned $0.14 earnings per share. As a group, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AMRX shares. Barclays lifted their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, December 19th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $10.80.

Insider Buying and Selling

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the transaction, the director now directly owns 1,888,886 shares of the company's stock, valued at $15,375,532.04. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,160,000 shares of company stock valued at $43,113,200 over the last three months. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.